45 Results for "

Leukemia stem cells

" in MedChemExpress (MCE) Product Catalog:
Products (45)

45 Results for "Leukemia stem cells" in MCE Product Catalog:

79
79 Publications Verification
Cat. No.: HY-N0488
CAS No.: 2068-78-2
Synonyms: Leurocristine sulfate; NSC-67574 sulfate; 22-Oxovincaleukoblastine sulfate
Vincristine (Leurocristine; NSC-67574; 22-Oxovincaleukoblastine) sulfate is a microtubule inhibitor that disrupts microtubule polymerization by binding to β-tubulin (with a Ki of 85 nM in bovine), arrests the cell cycle and induces apoptosis. Vincristine sulfate inhibits cell replication, tumor blood flow and the proliferation of various cancer cells, while triggering effects such as oxidative stress, inflammation, calcium overload, epithelial-mesenchymal transition and peripheral neuropathic pain. Vincristine sulfate upregulates the expression of various transporters and nuclear receptors, and enriches gastric cancer stem-like cells. Vincristine sulfate is used in research related to various tumors including acute lymphoblastic leukemia, lymphoma, melanoma, gastric cancer, solid tumors and sarcomas .
loading...
    loading...
79
79 Publications Verification
Cat. No.: HY-N0488A
CAS No.: 57-22-7
Synonyms: Leurocristine; NSC-67574; 22-Oxovincaleukoblastine
Vincristine (Leurocristine; NSC-67574; 22-Oxovincaleukoblastine) is a microtubule inhibitor that disrupts microtubule polymerization by binding to β-tubulin (with a Ki of 85 nM in bovine), arrests the cell cycle and induces apoptosis. Vincristine inhibits cell replication, tumor blood flow and the proliferation of various cancer cells, while triggering effects such as oxidative stress, inflammation, calcium overload, epithelial-mesenchymal transition and peripheral neuropathic pain. Vincristine upregulates the expression of various transporters and nuclear receptors, and enriches gastric cancer stem-like cells. Vincristine is used in research related to various tumors including acute lymphoblastic leukemia, lymphoma, melanoma, gastric cancer, solid tumors and sarcomas .
loading...
    loading...
7
7 Cited Publications
Cat. No.: HY-130800
CAS No.: 1860875-51-9
Purity:  99.76%
Synonyms: CC-90009
Eragidomide (CC-90009) is a GSPT1 Molecular Glue degrader. Eragidomide exhibits antiproliferative and pro-apoptotic (apoptosis) activities against acute myeloid leukemia cells. Eragidomide recruits the CRL4CRBN E3 ubiquitin ligase complex to selectively target GSPT1 for ubiquitination and proteasomal degradation. Eragidomide reduces leukemia cell engraftment and eliminates leukemia stem cells. Eragidomide promotes the activation of the GCN1/GCN2/ATF4 pathway and the integrated stress response pathway, inhibits global protein translation, promotes preferential translation of ATF4, and induces the accumulation of ATF4, CHOP and ATF3. The response to Eragidomide is regulated by the ILF2/ILF3 heterodimer complex, the mTOR signaling pathway and the integrated stress response. Eragidomide can be used in research related to acute myeloid leukemia and relapsed/refractory acute myeloid leukemia .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-16782
CAS No.: 945614-12-0
Synonyms: ARRY-614
Pexmetinib (ARRY-614) is an orally active dual Tie-2 and p38 MAPK inhibitor. Pexmetinib binds to Tie-2 and p38 MAPK in a "DFG-out" conformation, attenuates the phosphorylation of p38, inhibits STAT3 activation, reduces the promoter-binding activity of NFATc1, and decreases the expression of MMPs. Pexmetinib inhibits leukemia cell proliferation, abrogates TNF-α-mediated myelosuppression of healthy hematopoietic stem cells, stimulates hematopoiesis in primary myelodysplastic syndrome (MDS) samples, inhibits RANKL-induced osteoclast formation and bone resorption, and suppresses migration, invasion and induced osteolysis of breast cancer cells. Pexmetinib can be used in research related to myelodysplastic syndrome, acute myeloid leukemia and breast cancer-induced osteolysis .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-108420
CAS No.: 6314-70-1
Purity:  98.10%
Target:  

CDK

Research Areas:  

Cancer

INK4C-IN-2 is a p18 INK4C inhibitor. NK4C-IN-2 promotes hematopoietic stem cells (HSCs) division by inhibiting INK4C and activating CDK4/6, with an ED50 of 5.21 nM. INK4C-IN-2 shows no cytotoxic to normal 32D cells, HSCs, leukemia cell lines and myeloma cell lines .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-P99014
CAS No.: 1864871-20-4
Synonyms: ARGX-110

Research Areas:  

Inflammation/Immunology Cancer

Cusatuzumab (ARGX-110) is a selective competitive blocker targeting CD70 (with an equilibrium dissociation constant of 17 pM for binding to human CD70). Cusatuzumab also possesses enhanced antibody-dependent cell-mediated cytotoxicity (ADCC) activity. It is a humanized IgG1 monoclonal antibody, artificially synthesized through humanization and genetic engineering modifications (CH2 region mutation to enhance effector function). Cusatuzumab has a dual mechanism of action: firstly, it competitively blocks the interaction between CD70 and CD27, inhibiting the CD27-NF-κB signaling pathway, reducing regulatory T cell (Treg) activation and tumor cell proliferation; secondly, by enhancing binding to FcγRIIIa, it mediates ADCC and antibody-dependent cellular phagocytosis (ADCP), directly lysing CD70-positive tumor cells. Cusatuzumab can efficiently eliminate leukemia stem cells (LSCs), induce tumor cell differentiation and apoptosis, restore immune surveillance, and target CD70-positive tumors. Cusatuzumab is used in the study of acute myeloid leukemia (AML) .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-18948
CAS No.: 1816331-63-1
Research Areas:  

Cancer

GSK321 is a potent, selective mutant IDH1 inhibitor with IC50 values of 2.9, 3.8, 4.6 and 46 nM for R132G, R132C, R132H and WT IDH1, respectively, and >100-fold selectivity over IDH2. GSK321 induces decrease in intracellular α-Hydroxyglutaric acid (2-HG) (HY-113038B), abrogation of the myeloid differentiation block and induction of granulocytic differentiation at the level of leukemic blasts and more immature stem-like cells. GSK321can be used for research of acute myeloid leukemia (AML) and other cancers .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-120427
CAS No.: 154212-56-3
Purity:  98.82%
Synonyms: NSC 658586
Target:  

CCR CXCR HIV HSV

Research Areas:  

Infection Inflammation/Immunology

Cosalane (NSC 658586) is a CCR7 (IC50 = 2.43 μM) and CXCR2 antagonist (IC50 = 0.66 μM). Cosalane is an inhibitor of HIV replication with a wide range of activity against HIV-1 isolates, HIV-2, Rauscher murine leukemia virus, HSV-1, HSV-2 and human cytomegalovirus. Cosalane inhibits both attachment of gp120 to CD4. Cosalane inhibits human and murine CCR7 in response to both CCL19 and CCL21 agonists. Cosalane can be studied in research for HIV or attenuating acute graft-versus-host disease (aGVHD) in allogeneic hematopoietic stem cell transplantation (HSCT) .
loading...
    loading...
Cat. No.: HY-P99488
CAS No.: 2574591-89-0
Synonyms: JSP-191; AMG-191

Target:  

c-Kit

Research Areas:  

Inflammation/Immunology Cancer

Briquilimab (JSP-191 or AMG-191) is a humanized IgG1 monoclonal antibody that binds human CD117 (c-Kit). Briquilimab blocks the interaction between CD117 receptor and stem cell factor on various CD117 expressing tissues. Briquilimab can lead to inhibition of SCF/c-Kit signaling and MC apoptosis. Briquilimab is a non-toxic approach to target and deplete HSC, enabling blood and immune reconstitution with minimal toxicity with the other agents being used for transient immune suppression to prevent immunologic rejection. Briquilimab can be used in various disease research such as severe combined immunodeficiency (SCID), myelodyplastic syndromes (MDS), acute myeloid leukemia (AML), chronic spontaneous urticarial (CSU), chronic inducible urticarial (CIndU) and asthema .
loading...
    loading...
Cat. No.: HY-N1255
CAS No.: 6451-73-6
Synonyms: (-)-Scoulerine; Discretamine
Scoulerine ((-)-Scoulerine; Discretamine) hydrochloride is a multi-target inhibitor with anti-tumor and antioxidant activities. Scoulerine mainly targets the PI3K/Akt/mTOR signaling axis and α1D-adrenergic receptor, disrupts microtubule structure, and induces cell cycle arrest and apoptosis. Scoulerine effectively inhibits mitochondrial dehydrogenase activity, targets GABA receptors and BACE1, and suppresses the proliferation, migration, invasion, epithelial-mesenchymal transition and stem cell properties of cancer cells. Scoulerine also exhibits multiple pharmacological activities including anti-Plasmodium falciparum, antibacterial, antiemetic and antitussive effects, and regulates endoplasmic reticulum stress and mitochondrial function (modulates Bax, Bcl-2 and cytochrome c). Scoulerine is applicable to research related to leukemia, ovarian cancer, and colorectal cancer .
loading...
    loading...
Cat. No.: HY-N2732
CAS No.: 68097-13-2
Synonyms: 6-Prenyl-4',5,7-trihydroxyflavone; 6-C-Prenylapigenin
6-Prenylapigenin (6-Prenyl-4',5,7-trihydroxyflavone; 6-C-Prenylapigenin) is a prenylated flavonoid that exists in the stems and leaves of Maclura pomifera. 6-Prenylapigenin exhibits cytotoxicity against cancer cells such as leukemia cells and solid tumor cells .
loading...
    loading...
Cat. No.: HY-177578
NN3201 is a c-Kit-targeting antibody-drug conjugate (ADC) with high affinity (KD = 0.19 pM). NN3201 is composed of 4-(3-Tosyl-2-(tosylmethyl)propanoyl)benzoic acid-glu(PEG24-Me)-val-cit-NH-benzyloxyformic acid-MMAE (HY-178219) and an anti-c-Kit human monoclonal antibody NN2101 (HY-P991293). NN3201 rapidly internalizes and inhibits stem cell factor (SCF)-driven signaling, thereby delivering its payload to induce cell cycle arrest and apoptosis. NN3201 exhibits no Fc-mediated effector functions antibody-dependent cell-mediated cytotoxicity (ADCC)/complement-dependent cytotoxicity (CDC) due to reduced FcγR binding. NN3201 exhibits significant c-Kit-dependent anti-tumor efficacies in various tumor models. NN3201 can be used in small cell lung cancer (SCLC) and gastrointestinal stromal tumor (GIST) and acute myeloid leukemia (AML) research [1][2].
loading...
    loading...
Cat. No.: HY-P991381
Synonyms: PPMX-T003; TSP-A18
JST‑TfR09 (PPMX‑T003) is a human monoclonal antibody (mAb) targeting transferrin receptor 1 (TfR1/CD71). JST‑TfR09 blocks the binding of transferrin to TfR1, inhibits TfR1 internalization, and suppresses cellular iron uptake. JST‑TfR09 triggers ferritin degradation via activating the autolysosomal system, promotes ROS production and lipid peroxidation, and ultimately induces ferroptosis. JST‑TfR09 exhibits cytotoxicity toward human erythroblasts differentiated from hematopoietic stem cells. JST-TfR09 can be used in leukemia research. Recommended isotype control: Human IgG1 lambda, Isotype Control (HY-P99992) .
loading...
    loading...
Cat. No.: HY-128888B
CAS No.: 1816272-18-0
Purity:  98.62%
Research Areas:  

Cancer

(S,R)-GSK321 is the (S,R)-enantiomer of GSK321 (HY-18948). GSK321 is a potent, selective mutant IDH1 inhibitor with IC50 values of 2.9, 3.8, 4.6 and 46 nM for R132G, R132C, R132H and WT IDH1, respectively, and >100-fold selectivity over IDH2. GSK321 induces decrease in intracellular 2-HG, abrogation of the myeloid differentiation block and induction of granulocytic differentiation at the level of leukemic blasts and more immature stem-like cells. GSK321can be used for research of acute myeloid leukemia (AML) and other cancers .
loading...
    loading...
Cat. No.: HY-D1072
CAS No.: 53213-81-3
Synonyms: 3,3′-Dipentyloxacarbocyanine iodide
DiOC5(3) (3,3′-Dipentyloxacarbocyanine iodide) is a mitochondrial Fluorescent dye that alters membrane potential, and it also acts as an inhibitor of NADH-ubiquinone reductase (respiratory complex I). DiOC5(3) increases the NADH/NAD ratio and induces excessive production of ROS. DiOC5(3) induces Apoptosis. DiOC5(3) accumulates in the mitochondria of leukemia stem-like cells via organic anion-transporting polypeptides, specifically labels these cells, and inhibits their proliferation. DiOC5(3) enhances the cellular uptake of Hoechst 33342 (HY-15559), reduces Hoechst 33342-associated cytotoxicity, and improves the resolution of DNA content analysis by flow cytometry. DiOC5(3) shows no detectable fluorescence signal when excited in the 400-500 nm ultraviolet light range. DiOC5(3) is applicable to leukemia-related research .
loading...
    loading...
Cat. No.: HY-175164
Target:  

Apoptosis c-Myc

Research Areas:  

Cancer

SVC112 is a translation elongation inhibitor that prevents the cyclic dissociation of EF2 from the ribosome, thereby inhibiting the elongation step of translation. SVC112 shows activity in growth inhibition among cancer cell lines of various origins (acute myeloid leukemia (AML), multiple myeloma (Myeloma), colorectal cancer (CRC), and head and neck squamous cell carcinoma (HNSCC)). SVC112 preferentially impedes ribosomal processing of mRNAs, and decreaseds CSC-related proteins including Myc and Sox2. SVC112 induces apoptosis in hematologic cancer cell lines, while phosphorylation of c-Myc correlates with sensitivity to SVC112 in colorectal cancer cell lines. SVC112 inactivates HNSCC stem cells in vitro and prevents the regrowth of HNSCC tumor xenografts in mice. SVC112 can be used for the study of HNSCC .
loading...
    loading...
Cat. No.: HY-N0488S
CAS No.: 1246817-10-6
Synonyms: Leurocristine-d3 sulfate; NSC-67574-d3 sulfate; 22-Oxovincaleukoblastine-d3 sulfate
Vincristine-d3 sulfate is the deuterium labeled Vincristine sulfate. Vincristine sulfate (Leurocristine; NSC-67574; 22-Oxovincaleukoblastine) is a microtubule inhibitor that disrupts microtubule polymerization by binding to β-tubulin (with a Ki of 85 nM in bovine), arrests the cell cycle and induces apoptosis. Vincristine sulfate inhibits cell replication, tumor blood flow and the proliferation of various cancer cells, while triggering effects such as oxidative stress, inflammation, calcium overload, epithelial-mesenchymal transition and peripheral neuropathic pain. Vincristine sulfate upregulates the expression of various transporters and nuclear receptors, and enriches gastric cancer stem-like cells. Vincristine sulfate is used in research related to various tumors including acute lymphoblastic leukemia, lymphoma, melanoma, gastric cancer, solid tumors and sarcomas .
loading...
    loading...
Cat. No.: HY-169327
CAS No.: 2415160-21-1
Research Areas:  

Cancer

MD-265 is a PROTAC degrader targeting MDM2, which activates p53 in cancer cells carrying wild-type p53. MD-265 induces MDM2 degradation by recruiting the CRL4-CRBN ligase complex via the ubiquitination and proteasomal degradation pathway. MD-265 upregulates p53 target genes, induces apoptosis, reduces Mcl-1 levels, increases caspase-3 cleavage, and inhibits colony formation of wild-type p53 leukemia stem cells. MD-265 can be used in research related to leukemia and acute myeloid leukemia .
loading...
    loading...
Cat. No.: HY-179095
CAS No.: 2597345-07-6
UR241-2 is an IRAK4 inhibitor. UR241-2 suppresses IL-1–induced IRAK1/4 signaling, NF-κβ activation, and phosphorylation of p65 and p38. UR241-2 selectively inhibits leukemia stem cell clonogenicity. UR241-2 can serve as a ligand for target proteins for PROTAC, facilitating the development and design of PROTAC degraders for IRAK4. UR241-2 can be used in the research of acute myeloid leukemia .
loading...
    loading...
Cat. No.: HY-W106860
CAS No.: 51761-07-0
Synonyms: 3-Formylcarbazole
9H-Carbazole-3-carbaldehyde (3-Formylcarbazole) is a carbazole compound and an anticancer agent. 9H-Carbazole-3-carbaldehyde is present in the stems of Clausena lansium (Lour.) Skeels. 9H-Carbazole-3-carbaldehyde can be used in the research of cervical cancer, leukemia, non-small cell lung cancer and liver cancer .
loading...
    loading...